Gujarat Kidney & Super Speciality Ltd FY26 Results

Consolidated Revenue: ₹82.01 crore (up 103.8%)
Consolidated Net Profit: ₹16.81 crore (up 76.9%)

Reader Takeaway: Strong consolidated growth is a positive, but deferred CEO appointment and IPO object changes require investor attention.

What just happened

Gujarat Kidney and Super Speciality Ltd announced its financial results for the fiscal year ended March 31, 2026. The company reported a significant increase in both consolidated revenue and net profit. Consolidated revenue surged by 103.8% to ₹82.01 crore from ₹40.24 crore in the previous year. Consolidated net profit grew by 76.9% to ₹16.81 crore from ₹9.50 crore.

On a standalone basis, revenue from operations increased by 14.0% to ₹40.10 crore, and profit after tax rose by 8.7% to ₹9.90 crore.

The company's auditors provided an unmodified report on both standalone and consolidated results.

Why this matters

The substantial year-on-year growth, especially at the consolidated level, indicates strong operational performance and market traction. The unmodified audit report provides confidence in the financial reporting. However, the deferral of the CEO appointment and the upcoming postal ballot for 'Variation in Objects of IPO' introduce elements of uncertainty and require close monitoring by investors.

The backstory

Gujarat Kidney and Super Speciality Ltd is a healthcare provider. The company's Initial Public Offering (IPO) was launched with specific objectives for capital utilization. Changes to these objectives can signal a shift in the company's strategic direction and future investment plans.

What changes now

Investors will need to pay close attention to the outcome of the postal ballot regarding the variation in IPO objects, as this could impact future expansion or investment strategies. Additionally, any updates on the CEO appointment will be crucial for understanding the company's leadership outlook.

The company has also announced the appointment of Mr. Siddharth Atulbhai Shah as Internal Auditor for FY2026-27 and SPANJ & Associates as Secretarial Auditor for a five-year term, subject to member approval.

Risks to watch

The primary risks revolve around the potential implications of the 'Variation in Objects of IPO'. A change in how IPO funds are deployed could alter the expected growth trajectory or investment returns. The ongoing search for a CEO also presents a leadership continuity risk.

Peer comparison

While specific peer performance data for FY2026 is not yet available, the reported 103.8% consolidated revenue growth for Gujarat Kidney and Super Speciality Ltd appears robust within the healthcare sector.

Context metrics (time-bound)

• Consolidated Revenue FY2026: ₹82.01 crore (vs. ₹40.24 crore in FY2025)
• Consolidated Profit After Tax FY2026: ₹16.81 crore (vs. ₹9.50 crore in FY2025)
• Standalone Revenue FY2026: ₹40.10 crore (vs. ₹35.17 crore in FY2025)
• Standalone Profit After Tax FY2026: ₹9.90 crore (vs. ₹9.11 crore in FY2025)

What to track next

Investors should track the results of the postal ballot concerning the IPO object variation and any further announcements regarding the CEO appointment. Monitoring future financial disclosures will also be key to assessing the impact of these corporate actions.